Drug Trial Radar · NCT00650455
Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients
Last checked: Nov 20, 2026Latest source record: Jul 21, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
489
Actual
Start
Feb 2003
Primary completion
Jan 2005
Study completion Jan 2005
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Apr 1, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of the study were to evaluate the efficacy, safety, and tolerability of valdecoxib 10 mg once daily (QD) or naproxen 500 mg twice daily (BID) versus placebo, and to assess the efficacy of valdecoxib 10 mg QD versus naproxen 500 mg BID, in treating the signs and symptoms of rheumatoid arthritis (RA) in a severe Rheumatoid Arthritis population.
Conditions
- Arthritis, Rheumatoid
Interventions
valdecoxibDrug
valdecoxib 10 mg tablet once daily for 12 weeks
naproxenDrug
naproxen 500 mg capsule twice daily for 12 weeks
placeboDrug
placebo tablet every morning and capsule every evening for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- ACR-20 criteria responderTime frame: Week 12
Locations
55 sites in 2 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Huntsville, Alabama
Pfizer Investigational Site
Glendale, Arizona
Pfizer Investigational Site
Glendale, Arizona
Pfizer Investigational Site
Mesa, Arizona
Pfizer Investigational Site
Paradise Valley, Arizona
Pfizer Investigational Site
Phoenix, Arizona
Pfizer Investigational Site
Scottsdale, Arizona
Pfizer Investigational Site
Tucson, Arizona
Pfizer Investigational Site
Fullerton, California
Pfizer Investigational Site
Rancho Mirage, California
Pfizer Investigational Site
San Diego, California
Pfizer Investigational Site
Fort Lauderdale, Florida
Pfizer Investigational Site
Jacksonville, Florida
Pfizer Investigational Site
Jupiter, Florida
Pfizer Investigational Site
Ocala, Florida
Pfizer Investigational Site
Orlando, Florida
Pfizer Investigational Site
Palm Harbor, Florida
Pfizer Investigational Site
Tampa, Florida
Pfizer Investigational Site
West Palm Beach, Florida
Pfizer Investigational Site
Zephyrhills, Florida
Pfizer Investigational Site
Idaho Falls, Idaho
Pfizer Investigational Site
Chicago, Illinois
Pfizer Investigational Site
Springfield, Illinois
Pfizer Investigational Site
Indianapolis, Indiana
Pfizer Investigational Site
Frederick, Maryland
Pfizer Investigational Site
Greenbelt, Maryland
Pfizer Investigational Site
Lansing, Michigan
Pfizer Investigational Site
Jackson, Mississippi
Pfizer Investigational Site
Marlton, New Jersey
Pfizer Investigational Site
Passaic, New Jersey
Pfizer Investigational Site
Teaneck, New Jersey
Pfizer Investigational Site
Brooklyn, New York
Pfizer Investigational Site
New York, New York
Pfizer Investigational Site
New York, New York
Pfizer Investigational Site
Columbus, Ohio
Pfizer Investigational Site
Allentown, Pennsylvania
Pfizer Investigational Site
Duncansville, Pennsylvania
Pfizer Investigational Site
Erie, Pennsylvania
Pfizer Investigational Site
Johnstown, Pennsylvania
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.